Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Medical Informatics

Date Submitted: Jul 19, 2021
Date Accepted: Apr 21, 2022

The final, peer-reviewed published version of this preprint can be found here:

Medication-Wide Association Study Using Electronic Health Record Data of Prescription Medication Exposure and Multifetal Pregnancies: Retrospective Study

Davidson L, Canelón SP, Boland MR

Medication-Wide Association Study Using Electronic Health Record Data of Prescription Medication Exposure and Multifetal Pregnancies: Retrospective Study

JMIR Med Inform 2022;10(6):e32229

DOI: 10.2196/32229

PMID: 35671076

PMCID: 9214620

Prescription Medication Exposures and Multi-Fetal Pregnancies: Medication-Wide Association Study (MWAS) Using Electronic Health Record Data

  • Lena Davidson; 
  • Silvia P. Canelón; 
  • Mary Regina Boland

ABSTRACT

Background:

Medication-wide association study (MWAS) approach has been applied to observe prescription use and cancer risk, spontaneous preterm birth, acute myocardial infarction, acute liver failure, acute renal failure, and upper gastrointestinal ulcer.

Objective:

We aim to present methodology to systematically explore potential associations between medications prescribed during the pre-conception/first trimester period and occurrence of multiple birth (e.g., twins, triplets) in patients who delivered at Penn Medicine.

Methods:

We used electronic health record (EHR) data between 2010-2017 on patients who delivered babies at Penn Medicine, a healthcare system in Philadelphia and the Greater Philadelphia area.. We explored three logistic regression models: : a) Model 1 (no adjustment), b) Model 2 (adjustment for maternal age), and our final logistic regression c) Model 3 was calculated with multiple birth (MB) as our outcome of interest (binary outcome) and each medication as a binary variable while adjusting for maternal age and assisted reproductive technology (ART) and/or infertility diagnosis codes. Defined ART medications were used as our gold-standard of medications to evaluate performance.

Results:

Of the 63,334 total distinct deliveries in our cohort. 1,877 pregnancies (3.0%) were prescribed at least one medication during the pre-conception/first-trimester period. Of the 123 medications prescribed, we found 26 medications associated with MB (using nominal P values) and 10 medications associated MB (using Bonferroni adjustment) in the fully adjusted Model 3. We found that our Model 3 algorithm had an accuracy of 85% (using nominal P-values) and 89% (using Bonferroni adjusted P-values).

Conclusions:

Our work demonstrates the opportunities in applying the MWAS approach with EHR data to explore known associations with MB while identifying novel candidate medications for further study. Some of these medications are known ART-related medications, but diagnosis of infertility or ART usage was often missing from the EHR necessitating use of MWAS for MB to uncover these associations. Overall, we found 3 novel medications linked with MB that could be explored in further work.


 Citation

Please cite as:

Davidson L, Canelón SP, Boland MR

Medication-Wide Association Study Using Electronic Health Record Data of Prescription Medication Exposure and Multifetal Pregnancies: Retrospective Study

JMIR Med Inform 2022;10(6):e32229

DOI: 10.2196/32229

PMID: 35671076

PMCID: 9214620

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.